Long-term immunogenicity and efficacy of a recombinant hepatitis B vaccine in Egyptian children
AbstractIn 1992, Egypt adopted a hepatitis B vaccine schedule at 2, 4 and 6 months of age. We evaluated the long-term immunogenicity and efficacy of vaccination using this schedule in 180 children whose time lapse since last vaccination varied between 1 month and 5 years. None of the participants had clinical hepatitis, HBsAg was not detected in any participant and all but one had negative results for anti-HBc test. Although a high seroprotection rate [93.3%] was elicited 1 month after vaccination, there were low initial anti-HBs concentrations and both declined rapidly over time. Thus, the short interval [2 months] between the second and third doses of vaccine is less desirable in the long term. We recommend booster inoculations for all previously vaccinated children and a new vaccination schedule at 1, 2 and 9 months
El Sawy, I.H. & Mohamed, O.N. (1999). Long-term immunogenicity and efficacy of a recombinant hepatitis B vaccine in Egyptian children. http://www.who.int/iris/handle/10665/118780
EMHJ - Eastern Mediterranean Health Journal, 5 (5), 922-932, 1999
MetadataShow full item record
Showing items related by title and MeSH subject.
Response to hepatitis B virus vaccination in haemodialysis patients with and without hepatitis C infection Sorkhi, H.; Roushan, M.R.H.; Al Hashemi, G.H.; Dooki, M.R.E.; Bai, S. (2008)The aim of this study was to determine the efficacy of hepatitis B virus [HBV] vaccination and the response to vaccine in individuals on haemodialysis with and without HCV infection. From April 2000 to September 2003 all haemodialysis patients referred to the haemodialysis department in a Babol hospital received 4 microg vaccine intramuscularly at 0, 1, and 6 months. All were negative for HBV infection markers [HBcAb, HBsAg and HBsAb]. Of 62 patients, 53 [85.5%] responded to vaccination and 26 [49.1%] were high responders. All individuals with ...